Meeting
2022 ASCO Annual Meeting
Immune-related adverse events and immunotherapy efficacy in patients with cancer: A retrospective study.
Authors
Lyndsey L Prather
Baylor College of Medicine, Houston, TX
Lyndsey L Prather , Atif Ali , Hannah Wang , Wendy Du , Nan Chen , Aakash Sheth , Vlad Sandulache , Anita Lyn Sabichi , Jan Ole Kemnade , Daniel Ying Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other Checkpoint Inhibitors (Non-PD1/PDL1, Monotherapy, or Combination)
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2654)
DOI
10.1200/JCO.2022.40.16_suppl.2654
Abstract #
2654
Poster Bd #
308
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Gut microbiome to predict efficacy and immune-related toxicities in patients with advanced non-small cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy.
First Author: Taiki Hakozaki
Poster
2023 ASCO Annual Meeting
Patient-derived skin MicroOrganoSpheres and clinical response to immunotherapy.
First Author: Rikhia Chakraborty
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy and tolerability of immune checkpoint inhibitors in elderly patients with MSI/dMMR gastrointestinal cancers and impact of toxicities on efficacy: The immunoMSI cohort.
First Author: Leah Mailly-Giacchetti
Poster
2022 ASCO Annual Meeting
Association between immune-related adverse events and microbiome composition in patients with advanced non–small cell lung cancer treated with immunotherapy.
First Author: Marion Tonneau